Pendal Group Ltd lifted its position in shares of Agilent Technologies Inc (NYSE:A) by 17,076.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,227,965 shares of the medical research company’s stock after buying an additional 1,220,816 shares during the period. Agilent Technologies comprises about 1.1% of Pendal Group Ltd’s investment portfolio, making the stock its 29th largest holding. Pendal Group Ltd owned 0.39% of Agilent Technologies worth $71,925,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of A. We Are One Seven LLC bought a new position in shares of Agilent Technologies during the fourth quarter worth approximately $33,000. Clean Yield Group bought a new position in Agilent Technologies during the 4th quarter worth $48,000. Private Capital Group LLC increased its stake in Agilent Technologies by 168.8% during the 4th quarter. Private Capital Group LLC now owns 723 shares of the medical research company’s stock worth $49,000 after acquiring an additional 454 shares during the period. Cornerstone Advisors Inc. increased its stake in Agilent Technologies by 33.8% during the 4th quarter. Cornerstone Advisors Inc. now owns 811 shares of the medical research company’s stock worth $55,000 after acquiring an additional 205 shares during the period. Finally, Shine Investment Advisory Services Inc. increased its stake in Agilent Technologies by 65.5% during the 4th quarter. Shine Investment Advisory Services Inc. now owns 907 shares of the medical research company’s stock worth $61,000 after acquiring an additional 359 shares during the period.
In other news, CEO Michael R. Mcmullen sold 15,923 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $73.20, for a total value of $1,165,563.60. Following the transaction, the chief executive officer now owns 492,546 shares in the company, valued at approximately $36,054,367.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael R. Mcmullen sold 17,491 shares of the business’s stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $75.00, for a total value of $1,311,825.00. Following the completion of the transaction, the chief executive officer now owns 456,430 shares in the company, valued at approximately $34,232,250. The disclosure for this sale can be found here. Insiders have sold a total of 43,816 shares of company stock valued at $3,242,727 in the last quarter.
Shares of Agilent Technologies stock opened at $77.25 on Thursday. Agilent Technologies Inc has a one year low of $60.42 and a one year high of $77.49. The stock has a market capitalization of $24.48 billion, a P/E ratio of 27.69, a PEG ratio of 2.12 and a beta of 1.33. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.29 and a quick ratio of 2.74.
Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 19th. The medical research company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The business had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the company posted $0.67 EPS. The firm’s revenue was up 8.8% compared to the same quarter last year. Analysts expect that Agilent Technologies Inc will post 3.04 EPS for the current fiscal year.
Agilent Technologies declared that its Board of Directors has authorized a share repurchase program on Monday, November 19th that allows the company to repurchase $1.75 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 8.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.
WARNING: “Agilent Technologies Inc (A) Shares Bought by Pendal Group Ltd” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/02/14/pendal-group-ltd-acquires-1220816-shares-of-agilent-technologies-inc-a.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.